[go: up one dir, main page]

PL1694361T3 - Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii - Google Patents

Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii

Info

Publication number
PL1694361T3
PL1694361T3 PL04806560T PL04806560T PL1694361T3 PL 1694361 T3 PL1694361 T3 PL 1694361T3 PL 04806560 T PL04806560 T PL 04806560T PL 04806560 T PL04806560 T PL 04806560T PL 1694361 T3 PL1694361 T3 PL 1694361T3
Authority
PL
Poland
Prior art keywords
mammalian cells
phagocytic
phagocytic mammalian
minicells
gene delivery
Prior art date
Application number
PL04806560T
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Publication of PL1694361T3 publication Critical patent/PL1694361T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
PL04806560T 2003-12-09 2004-12-08 Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii PL1694361T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52776403P 2003-12-09 2003-12-09
PCT/IB2004/004406 WO2005056749A2 (en) 2003-12-09 2004-12-08 Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
EP04806560A EP1694361B1 (en) 2003-12-09 2004-12-08 Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells

Publications (1)

Publication Number Publication Date
PL1694361T3 true PL1694361T3 (pl) 2011-08-31

Family

ID=34676775

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04806560T PL1694361T3 (pl) 2003-12-09 2004-12-08 Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii

Country Status (14)

Country Link
US (3) US9169495B2 (pl)
EP (2) EP1694361B1 (pl)
JP (1) JP4332558B2 (pl)
CN (2) CN1913923B (pl)
AT (1) ATE501735T1 (pl)
AU (1) AU2004297414C1 (pl)
CA (1) CA2549840C (pl)
DE (1) DE602004031870D1 (pl)
DK (1) DK1694361T3 (pl)
ES (1) ES2362881T3 (pl)
NZ (1) NZ547983A (pl)
PL (1) PL1694361T3 (pl)
PT (1) PT1694361E (pl)
WO (1) WO2005056749A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2302063B1 (en) * 2001-10-15 2016-05-04 EnGeneIC Molecular Delivery Pty Ltd. Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo
US7611885B2 (en) * 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
DK1694361T3 (da) 2003-12-09 2011-06-06 Engeneic Molecular Delivery Pty Ltd Målrettet levering til ikke-phagocytiske pattedyrceller via bakterielt afledte intakte miniceller
US8772013B2 (en) * 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
PT1718338E (pt) 2004-02-02 2015-09-21 Engeneic Molecular Delivery Pty Ltd Composições e métodos de libertação direcionada de fármacos in vitro e in vivo por meio de minicélulas intactas derivadas de bactérias
HUE024999T2 (en) 2004-08-26 2016-02-29 Engeneic Molecular Delivery Pty Ltd Introducing functional nucleic acids into mammalian cells with bacterial intact minicells
CA2658058C (en) * 2006-06-23 2016-08-23 Engeneic Molecular Delivery Pty Ltd. Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
CA2933978C (en) 2007-03-30 2018-08-21 Engeneic Molecular Delivery Pty. Ltd. Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
US20100112670A1 (en) 2008-06-25 2010-05-06 Vaxiion Therapeutics, Inc. Regulated genetic suicide mechanism compositions and methods
AU2012217728B2 (en) 2011-02-15 2017-04-27 Vaxiion Therapeutics, Llc Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
SMT202000676T1 (it) 2011-12-13 2021-01-05 Engeneic Molecular Delivery Pty Ltd Minicellule intatte di derivazione batterica per veicolazione di agenti terapeutici a tumori cerebrali
WO2014055682A1 (en) 2012-10-02 2014-04-10 Vaxiion Therapeutics, Inc. Immunomodulatory minicells and methods of use
US9017698B2 (en) * 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
NZ718148A (en) 2013-10-04 2022-02-25 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
WO2016051389A1 (en) 2014-10-03 2016-04-07 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
KR102687638B1 (ko) 2015-08-04 2024-07-22 벡션 테라퓨틱스 엘엘씨 이온화 방사선 조사 멸균된 박테리아 미니세포 기반 생물 약제
US10894093B2 (en) 2016-04-15 2021-01-19 Cellectis Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
US20190328783A1 (en) * 2016-04-15 2019-10-31 Cellectis A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
EA201990689A1 (ru) 2016-10-06 2019-10-31 Бактериальные мини-клетки для доставки адъювантов на основе нуклеиновых кислот и способы их применения
US11167008B2 (en) 2016-11-23 2021-11-09 Vaxiion Therapeutics, Llc Immunomodulatory and oncolytic minicells and methods of use
CN112689511A (zh) 2018-07-23 2021-04-20 安吉尼科分子传输公司 包含细菌源微细胞的组合物及其使用方法
CN113507936A (zh) 2019-01-04 2021-10-15 安吉尼科分子传输公司 用于治疗赘生性疾病的包封的糖脂抗原
WO2020222161A1 (en) * 2019-05-01 2020-11-05 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived intact minicells for theranostic applications

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496778A (en) 1983-10-03 1985-01-29 Exxon Research & Engineering Co. Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5221479A (en) * 1991-02-15 1993-06-22 Fuji Photo Film Co., Ltd. Filtration system
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
WO1996001653A1 (en) 1994-07-11 1996-01-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
JP2001501834A (ja) 1997-03-19 2001-02-13 ザイモジェネティクス，インコーポレイティド 分泌される唾液ｚｓｉｇ３２ポリペプチド
US20030004123A1 (en) * 1997-06-26 2003-01-02 Boucher Richard C. Targeted gene transfer using G protein coupled receptors
CA2302316A1 (en) * 1997-09-15 1999-03-25 Genetic Immunity, Llc. Method of delivering genes to antigen presenting cells of the skin
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
CN1375004A (zh) 1999-04-21 2002-10-16 惠氏公司 抑制多核苷酸序列的功能的方法和组合物
AU2001294520A1 (en) 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
IL157794A0 (en) * 2001-03-07 2004-03-28 Childrens Medical Center Method to screen peptide display libraries using minicell display
US7011946B2 (en) 2001-05-22 2006-03-14 Trustees Of Tufts College In vivo assay for identification of antimicrobial agents
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20030194714A1 (en) 2001-06-05 2003-10-16 Sabbadini Roger A. Minicell-based transformation
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
EP2302063B1 (en) * 2001-10-15 2016-05-04 EnGeneIC Molecular Delivery Pty Ltd. Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo
WO2003072014A2 (en) 2002-02-25 2003-09-04 Mpex Bioscience, Inc. Minicell compositions and methods
US20030203481A1 (en) * 2002-02-25 2003-10-30 Surber Mark W. Conjugated minicells
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
DK1694361T3 (da) 2003-12-09 2011-06-06 Engeneic Molecular Delivery Pty Ltd Målrettet levering til ikke-phagocytiske pattedyrceller via bakterielt afledte intakte miniceller
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
HUE024999T2 (en) 2004-08-26 2016-02-29 Engeneic Molecular Delivery Pty Ltd Introducing functional nucleic acids into mammalian cells with bacterial intact minicells
JP5601756B2 (ja) 2004-12-17 2014-10-08 ベス イスラエル デアコネス メディカル センター， インコーポレイテッド 細菌によって媒介される遺伝子サイレンシングのための組成物およびその使用方法
CA2658058C (en) 2006-06-23 2016-08-23 Engeneic Molecular Delivery Pty Ltd. Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

Also Published As

Publication number Publication date
CN1913923B (zh) 2010-12-08
US20180369416A1 (en) 2018-12-27
EP1694361B1 (en) 2011-03-16
WO2005056749A2 (en) 2005-06-23
CN101954095A (zh) 2011-01-26
EP1694361A2 (en) 2006-08-30
US9169495B2 (en) 2015-10-27
CA2549840C (en) 2012-03-20
DK1694361T3 (da) 2011-06-06
CA2549840A1 (en) 2005-06-23
DE602004031870D1 (de) 2011-04-28
HK1095090A1 (en) 2007-04-27
ATE501735T1 (de) 2011-04-15
US20150343092A1 (en) 2015-12-03
CN1913923A (zh) 2007-02-14
US10583200B2 (en) 2020-03-10
JP4332558B2 (ja) 2009-09-16
CN101954095B (zh) 2013-03-13
ES2362881T3 (es) 2011-07-14
WO2005056749A3 (en) 2005-10-13
PT1694361E (pt) 2011-06-27
US9987377B2 (en) 2018-06-05
EP1694361A4 (en) 2006-12-13
AU2004297414C1 (en) 2009-06-25
US20070237744A1 (en) 2007-10-11
NZ547983A (en) 2009-05-31
JP2007534310A (ja) 2007-11-29
AU2004297414B2 (en) 2008-10-30
EP2295084A1 (en) 2011-03-16
AU2004297414A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
EP1694361A4 (en) TARGETED GENETIC DELIVERY OF NON-PHAGOCYTIC MAMMALIAN CELLS VIA BACTERIALLY OBTAINED INTACT MINIMITIES
US10507246B2 (en) TDNs-AS1411-nucleic acid drug nanocomposite based drug delivery system and preparation method thereof
IL207446A0 (en) Acid alpha-glucosidase and fragments thereof
PL2386640T3 (pl) Dostarczanie funkcjonalnych kwasów nukleinowych do komórek ssaczych za pośrednictwem nienaruszonych minikomórek pochodzenia bakteryjnego
WO2004050884A3 (de) Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
EP1709194A4 (en) DISTRIBUTION OF DNA OR RNA VIA NEXI OF HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SIRNA
WO2008012695A3 (en) Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
WO2005007196A3 (en) Lipid encapsulated interfering rna
AU2025202594A9 (en) Modified Cpf1 guide RNA
WO2005117991A3 (en) Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
SG169373A1 (en) Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
WO2003072711A3 (en) Method of using modified oligonucleotides for hepatic delivery
EP1766035A4 (en) INTERFERING RNA ENCAPSULATED IN LIPIDS
AP1427A (en) Method of delivering genes to antigen presenting cells of the skin.
AU2014208251B2 (en) Carbohydrate conjugates as delivery agents for oligonucleotides
WO2010121130A3 (en) Molecular delivery with nanowires
EP4267723A1 (en) Compositions and methods for genetically modifying ciita in a cell
GB9816138D0 (en) Organic compounds
ATE310806T1 (de) Immunmodulation mittels genetischer modifikation von dendritischen zellen und b-zellen
DK1585822T3 (da) Promotorvarianter til ekspression af gener i en fungal celle
WO2007044627A3 (en) Compositions and methods for delivery of interfering rna
ATE393574T1 (de) Zur glucoseregulierten produktion von menschlichem insulin in somatischen zelllinien geeignete nukleinsäurekonstrukte
AR041953A1 (es) Secuencias de adn a partir de la region genomica tcd de photorhabdus luminiscens
WO2009129523A3 (en) Compositions and methods for nucleic acid delivery
WO2003000894A9 (fr) Vaccins polynucleotides